Optic Neuritis Clinical Trial
Official title:
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of OCS-05 in Patients With Acute Optic Neuritis
To evaluate the safety and tolerability of OCS-05 compared to placebo in patients with acute optic neuritis (AON) receiving the standard of care
ACUITY is a phase 2, multicentric, two-arm, randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of OCS-05 compared to placebo in patients with acute optic neuritis (AON) receiving the standard of care. Fourty-two (42) eligible patients aged 18 to 60, with recent onset (visual loss symptoms) of unilateral AON (idiopathic or associated with multiple sclerosis) will be randomized to receive OCS-05 or placebo. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Unknown status |
NCT00261326 -
Simvastatin Treatment of Patients With Acute Optic Neuritis
|
Phase 3 | |
| Active, not recruiting |
NCT03963310 -
Optical Coherence Tomography and Optic Neuritis Not Related to Multiple Sclerosis
|
||
| Recruiting |
NCT03586557 -
Effectiveness of Plasma Exchange in Treating With Severe Acute AQP4-Ab Positive Optic Neuritis
|
N/A | |
| Recruiting |
NCT05487989 -
VIsual Pathways Model in Neuro-inflammatory Disorders
|
||
| Terminated |
NCT04131764 -
Diagnosis of ON With or Without MS or NMOSD
|
||
| Not yet recruiting |
NCT06453694 -
Efgartigimod for the Treatment of Acute Optic Neuritis
|
Phase 2 | |
| Completed |
NCT01962571 -
Treatment of Optic Neuritis With Erythropoietin: a Randomised, Double-blind, Placebo-controlled Trial
|
Phase 3 | |
| Recruiting |
NCT03302585 -
High-Dose Vitamin D Induction in Optic Neuritis
|
Phase 2 | |
| Recruiting |
NCT02886377 -
The Correlation Between AQP-4 Ab and the Visual Function of Patients With Demyelinating ON at Onset
|
N/A | |
| Completed |
NCT01987167 -
Defining the Functional and Neuro-Protective Potential of ACTHAR in Acute Optic Neuritis
|
Early Phase 1 | |
| Completed |
NCT01451593 -
Neuroprotection With Phenytoin in Optic Neuritis
|
Phase 2 | |
| Completed |
NCT03630497 -
BN201 SAD MAD Study in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT01337986 -
Ampyra for Optic Neuritis in Multiple Sclerosis
|
Phase 2/Phase 3 | |
| Completed |
NCT01274702 -
Visual Reconstitution Therapy After Optic Neuritis
|
Phase 2 | |
| Active, not recruiting |
NCT00445367 -
Biobank For MS And Other Demyelinating Diseases
|
||
| Withdrawn |
NCT00037115 -
Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event.
|
Phase 4 | |
| Not yet recruiting |
NCT06389968 -
Light Stimulation to Improve Visual Function After Optic Neuritis in Persons With Multiple Sclerosis
|
N/A | |
| Recruiting |
NCT04257734 -
Epidemiologic and Clinical Characteristics of Optic Neuritis in China
|
||
| Completed |
NCT03753893 -
Ocular Manifestations in Rheumatic Diseases
|
||
| Completed |
NCT02939937 -
Effect of Phenytoin on the Ganglion Cell Layer in Patients With Optic Neuritis
|
Phase 2 |